{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T01:22:25Z","timestamp":1712020945939},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1700","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>The FDA has approved the complement C5 inhibitor zilucoplan (Zilbrysq \u2013 UCB) for once-daily subcutaneous treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody-positive. Zilucoplan is the first complement inhibitor to be approved for treatment of myasthenia gravis that can be self-administered.<\/jats:p>","DOI":"10.58347\/tml.2024.1700c","type":"journal-article","created":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T17:23:56Z","timestamp":1711992236000},"page":"60-62","source":"Crossref","is-referenced-by-count":0,"title":["Zilucoplan (Zilbrysq) for Myasthenia Gravis"],"prefix":"10.58347","volume":"66","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"37151","published-online":{"date-parts":[[2024,4,15]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T17:23:56Z","timestamp":1711992236000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1700c"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":0,"journal-issue":{"issue":"1700","published-online":{"date-parts":[[2024,4,15]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1700c","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]}}}